Immune checkpoint inhibitors (ICIs) in the treatment of MTAP-null cancers have garnered interest in the research field due to the synergistic effect of PRMT5 inhibition with anti-programmed cell death protein (PD1) drugs (Table 3). Here, PRMT5 is linked to cancer.